Breast Cancer Clinical Trials | Norton Healthcare Louisville, Ky.

Breast Cancer Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous breast cancer clinical trials, our specialist physicians have access to innovative treatments.

Learn more about participating in a clinical trial at Norton Healthcare.

Active breast cancer clinical trials include:

Breast Cancer

Randomized, Non-comparative Neoadjuvant Phase II Study in Postmenopausal Women with ER+/HER2- Breast Cancer >/=2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole (CheckMate 7A8)

Triple Negative Breast Cancer (TNBC)

A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Ce

Advanced Solid Tumors

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors

Breast Cancer

A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as an Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer (New Adjuvant TriAl with Ri

Breast Cancer

A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced

Lung Cancer/ Breast Cancer

A Phase 1 Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses and treatment intensification of a vaccine-based immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for advanced non-small cell lung cancer and metastatic tripl

Cancer

A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination with Nivolumab, an anti-PD-1 antibody, for Subjects with HER2-expressing Advanced Breast

Metastatic Breast Cancer

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A,), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS ADO-TRASTUZUMAB EMTANSINE (T-DM1) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER S

Metastatic Breast Cancer

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER S

Breast Cancer

Elacestrant Monotherapy Vs. Standard Of Care For The Treatment Of Patients With Er+/Her2- Advanced Breast Cancer Following Cdk4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial (EMERALD)

Multiple Sclerosis (MS)

An Observational Study Of Ocrelizumab-Treated Patients With Multiple Sclerosis To Determine The Incidence And Mortality Rates Of Breast Cancer And All Malignancies (VERISMO STUDY)

Breast Cancer

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast […]

Breast Cancer

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Education

Effects of a Smartphone App on Compliance and Function in Patients with Breast Cancer

Breast Cancer

NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Breast Cancer

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axilla

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3501

Can coloring or straightening hair increase breast cancer risk?

The link between chemicals and cancer is often in question. The latest is a study that found a higher risk of developing breast cancer among women who used permanent hair dye or hair straighteners. This […]

Read Full Story

Art therapist’s breast cancer journey fuels passion to help others with the disease

While Leigh Galloway undergoes her last chemotherapy treatment before a double mastectomy, she and Laura Chamberlin are engrossed in a watercolor. Like she does often with Laura, an expressive art therapist with Norton Cancer Institute […]

Read Full Story

Breast cancer in men is real and can be deadly

Breast cancer in men is serious and particularly deadly, partly because it isn’t discussed. There are some body parts we’re born with whether we’re male or female — including breast tissue. The breast tissue doesn’t […]

Read Full Story

It’s Breast Cancer Awareness Month — remember to schedule your mammogram

October is Breast Cancer Awareness Month, an annual reminder to do a self-check for signs and symptoms, schedule a mammogram and keep in mind those who are fighting breast cancer or have lost their lives [...]

Read Full Story

Cokie Roberts’ 17-year breast cancer survival points to medical advances

When television journalist Cokie Roberts was diagnosed with breast cancer in 2002, she had reason to be optimistic. The 15-year survival rate for breast cancer patients was about 70%, meaning the odds were with her, […]

Read Full Story
Related Stories

Can coloring or straightening hair increase breast cancer risk?

The link between chemicals and cancer is often in question. The latest is a study that found a higher risk of developing breast cancer among women who used permanent hair dye or hair straighteners. This […]

Read Full Story

Art therapist’s breast cancer journey fuels passion to help others with the disease

While Leigh Galloway undergoes her last chemotherapy treatment before a double mastectomy, she and Laura Chamberlin are engrossed in a watercolor. Like she does often with Laura, an expressive art therapist with Norton Cancer Institute […]

Read Full Story

Breast cancer in men is real and can be deadly

Breast cancer in men is serious and particularly deadly, partly because it isn’t discussed. There are some body parts we’re born with whether we’re male or female — including breast tissue. The breast tissue doesn’t […]

Read Full Story

It’s Breast Cancer Awareness Month — remember to schedule your mammogram

October is Breast Cancer Awareness Month, an annual reminder to do a self-check for signs and symptoms, schedule a mammogram and keep in mind those who are fighting breast cancer or have lost their lives [...]

Read Full Story

Cokie Roberts’ 17-year breast cancer survival points to medical advances

When television journalist Cokie Roberts was diagnosed with breast cancer in 2002, she had reason to be optimistic. The 15-year survival rate for breast cancer patients was about 70%, meaning the odds were with her, […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.